The U.S. government is fine-tuning the rules for how it will negotiate drug prices within Medicare when the second round of talks with drugmakers begins early next year. Specifically, officials at the ...
The second cycle of the Medicare Drug Price Negotiation Program will offer pharma companies more time and chances to submit counteroffers during the price talks, which will take place throughout 2025.
The intrinsic value estimate for Johnson & Johnson has shifted slightly, with the fair value moving from US$252.42 to ...
Taking advantage of a broken patent system, Big Pharma is making minor tweaks to medications just to keep affordable generics off the market, a new report suggests. They’ve made billions of dollars in ...
A new generation of malaria drugs failed clinical trials, in part because they were hard to swallow. UCSF chemists remodeled their structures to make them more soluble, while maintaining their ...
About half of patients with obesity but not diabetes who were enrolled in a phase IIb trial of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, dropped out due to side effects, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results